All Posts

February 3, 2026 Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules,announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification inNovember of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index(mSI™), a score that is intended to help radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The com

Don't let a lung nodule go unnoticed Incidental findings on CT scans offer a powerful opportunity. While concerns about radiation...

The nodules just keep piling up..... Each year, millions of lung nodules are detected, yet only a small fraction (5%) are malignant,...

“AI in medicine is like self-driving cars, we all know it's the future and will save a lot of lives, but figuring out who uses it, who...

TriHealth Advances Lung Cancer Diagnosis and Treatment Through New AI Partnership Cincinnati, OH – April X, 2025  – TriHealth, a...

Lung nodules, although common, can be a cause for concern due to their potential link to lung cancer. Managing lung nodules requires...

Lung nodules are a common finding on CT scans, whether through routine lung cancer screening (LDCT) or incidental detection (ILN). Yet,...

Innovative Lung Nodule Care Solutions Lung nodules are small growths on the lungs that are quite common and are usually detected during...